Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
AstraZeneca
Deloitte
Queensland Health
US Army
Argus Health
Johnson and Johnson
McKinsey
Healthtrust

Generated: June 20, 2018

DrugPatentWatch Database Preview

EMEND Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Emend patents expire, and when can generic versions of Emend launch?

Emend is a drug marketed by Merck, Msd Merck Co, and Merck And Co Inc. and is included in three NDAs. There are three patents protecting this drug and four Paragraph IV challenges.

This drug has one hundred and twenty-five patent family members in forty-eight countries.

The generic ingredient in EMEND is fosaprepitant dimeglumine. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.
Drug patent expirations by year for EMEND
Synonyms for EMEND
(1R,2R,3R)-Aprepitant
170729-80-3
1NF15YR6UY
221350-96-5
3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-1H-1,2,4-triazol-5(4H)-one
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one
3-[((2R,5-bis(trifluoromethyl)benzyl]oxy}morpholino)methyl]-.delta.2-1,2,4-triazolin-5-one
3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-one
3-[2-{1-[3,5-di(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)-1,4-oxazinan-4-ylmethyl]-4,5-dihydro-1H-1,2,4-triazol-5-one
3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-4,5-dihydro-1H-1,2,4-triazol-5-one
3H-1,2,4-Triazol-3-one, 5-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-
3H-1,2,4-Triazol-3-one, 5-((2-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-, (2R-(2alpha(R*),3alpha))-
3H-1,4-Triazol-3-one, 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-
5-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-2H-1,2,4-triazol-3(4H)-one
5-[(2R,3S)-2-[(R)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-3-(4-fluoro-phenyl)-morpholin-4-ylmethyl]-2,4-dihydro-[1,2,4]triazol-3-one
5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(Trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one
5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one
5-[2-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-3-(4-fluoro-phenyl)-morpholin-4-ylmethyl]-2,4-dihydro-[1,2,4]triazol-3-one
5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
729A803
AB01274775_02
AB01274775-01
AB01275535-01
ABP000600
AC1OCFCG
AK322012
AKOS015895498
AKOS015969344
AOB6779
Aprepitant
Aprepitant (JAN/USAN/INN)
Aprepitant (MK-0869 L-754030)
Aprepitant (MK-0869)
Aprepitant [USAN:INN:JAN]
Aprepitant [USAN]
Aprepitant,MK-0869, L-754030, Emend
Aprepitant(MK-0869)
aprepitantum
AS-14638
ATALOFNDEOCMKK-OITMNORJSA-N
BCP9000312
BDBM50220136
BRD-K52827117-001-01-6
C21555
C23H21F7N4O3
CCG-220747
CHEBI:499361
CHEMBL1471
Cinvanti
CS-0487
CTK4D3687
D02968
D0GU4K
DB00673
Emend (TN)
eMende
EX-A212
GTPL3490
HMS2090N12
HY-10052
I06-1151
L 754030
L-754030
L982
MK 0869
MK 869
MK-0869
MK-869
MK-869, L-754030, Emend, Aprepitant
MK0869
MLS006011068
MolPort-006-392-367
MolPort-009-679-399
NSC-748825
NSC748825
ONO 7436
ONO-7436
Q-200647
RL02193
s1189
SCHEMBL264924
SMR002530053
SR-05000001531
SR-05000001531-1
UNII-1NF15YR6UY
W-5373
ZINC27428713

US Patents and Regulatory Information for EMEND

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Msd Merck Co EMEND aprepitant FOR SUSPENSION;ORAL 207865-001 Dec 17, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Msd Merck Co EMEND aprepitant FOR SUSPENSION;ORAL 207865-001 Dec 17, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for EMEND

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for EMEND
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe for Oral Suspension 125 mg/Kit ➤ Subscribe 2016-11-23
➤ Subscribe Injection 150 mg/vial ➤ Subscribe 2012-01-25
➤ Subscribe Injection 115 mg/vial ➤ Subscribe 2012-01-25
➤ Subscribe Capsule 40 mg, 80 mg and 125 mg ➤ Subscribe 2008-11-03

Non-Orange Book US Patents for EMEND

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,229,010 Polymorphic form of a tachykinin receptor antagonist ➤ Try a Free Trial
6,583,142 Polymorphic form of a tachykinin receptor antagonist ➤ Try a Free Trial
5,512,570 Treatment of emesis with morpholine tachykinin receptor antagonists ➤ Try a Free Trial
6,432,953 Polymorphic form of a tachykinin receptor antagonist ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for EMEND

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0019 France ➤ Try a Free Trial PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
2004 Austria ➤ Try a Free Trial PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
2004002,C0734381 Lithuania ➤ Try a Free Trial PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
C/GB04/011 United Kingdom ➤ Try a Free Trial PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
McKesson
Queensland Health
Citi
Moodys
Mallinckrodt
McKinsey
Chinese Patent Office
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.